Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01567501
Other study ID # Ipca/ARL/059
Secondary ID
Status Completed
Phase Phase 1
First received March 23, 2012
Last updated November 30, 2012
Start date February 2012
Est. completion date March 2012

Study information

Verified date November 2012
Source IPCA Laboratories Ltd.
Contact n/a
Is FDA regulated No
Health authority India: Ministry of HealthUnited States: Institutional Review Board
Study type Interventional

Clinical Trial Summary

This is a single-dose, Randomized, two-period,cross over pivotal study. The purpose of this study is to assess the bioequivalence between Test Product and the corresponding Reference Product under fed condition in normal, healthy, adult, human subjects.


Description:

Primary Objective of this pivotal study was to assess the bioequivalence between Test Product: Levocetirizine Dihydrochloride 5 mg Tablets of M/s Ipca Laboratories Limited, India and the corresponding Reference Product: Xyzal® (levocetirizine dihydrochloride) 5 mg Tablets of M/s UCB Inc.,USA, under fed condition in normal, healthy, adult, human subjects in a randomized crossover study.

Secondary Objective was to monitor the safety and tolerability of a single oral dose of Levocetirizine Dihydrochloride 5 mg Tablets in normal,healthy, adult, human subjects.

The study was conducted with 28 healthy adult subjects. In each study period, a single 5 mg dose of either test or reference was administered to the subjects as per the randomization schedule in each study period with about 240 mL of water at ambient temperature in sitting position.

The duration of the clinical phase was approximately 11 days including washout period of at least 7 days between administrations of study drug in each study period.


Recruitment information / eligibility

Status Completed
Enrollment 28
Est. completion date March 2012
Est. primary completion date March 2012
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 18 Years to 45 Years
Eligibility Inclusion Criteria:

- Male and non-pregnant female human subjects, age in the range of 18 - 45 years (both inclusive).

- Body weight within ± 15% of ideal weight as related to height and body frame according to Life Insurance Corporation (LIC) Chart.

- Subjects with normal findings as determined by baseline history, physical examination and vital signs (blood pressure, pulse rate, respiration rate and oral temperature).

- Subjects with clinically acceptable findings as determined by haemogram, biochemistry, serology (HIV, Hepatitis B and Hepatitis C), urinalysis, 12 lead ECG and chest X-ray (chest X-ray if required).

- Willingness to follow the protocol requirements as evidenced by written informed consent.

- Confirming and agreeing to, not using any prescription and over the counter medications including vitamins and minerals for 14 days prior to study and during the course of the study.

- No history of drug abuse in the past one year.

- Non-smokers and non-alcoholics.

- For female subject is child bearing potential practicing acceptable method of birth control for the duration of the study as judged by Investigator such as Condom, Foams, Jellies,Diaphragm, Intrauterine device and Abstinence

- Is surgically sterile (bilateral tubal ligation, bilateral oophorectomy or hysterectomy has been performed on the subject).

Exclusion Criteria:

- Known history of hypersensitivity to Levocetirizine or to Cetirizine, or related drugs.

- Requiring medication for any ailment having enzyme-modifying activity in the previous 28 days, prior to dosing day.

- Any medical or surgical conditions, which might significantly interfere with the functioning of gastrointestinal tract, blood-forming organs etc.

- History of cardiovascular, renal, hepatic, ophthalmic, pulmonary, neurological, metabolic, hematological, gastrointestinal, endocrine, immunological or psychiatric diseases and bleeding tendency.

- Participation in a clinical drug study or bioequivalence study within 90 days prior to present study.

- History of malignancy or other serious diseases.

- Refusal to abstain from food for at least ten (10.00) hours prior to receiving the high-fat and high-calorie breakfast and for at least four (04.00) hours post-dose, in each study period.

- Any contraindication to blood sampling or difficulty in accessibility of veins.

- Refusal to abstain from fluid for at least 01.00 hour prior to study drug administration and for at least 01.00 additional hour post-dose, in each study period except about 240 mL of water given during administration of study drug.

- Refusal to avoid the use of xanthine-containing food or beverages (chocolates,tea, coffee or cola drinks) or fruit juice/grapefruit juice and any alcoholic products for 48.00 hours prior to dosing until the last blood sample collection of last study period.

- Blood donation within 90 days prior to the commencement of the study.

- Subjects with positive HIV tests or Hepatitis-B or Hepatitis-C tests.

- Found positive in breath alcohol test done before check-in for each study period.

- Found positive in urine test for drugs of abuse done before check-in for each study period.

- Refusal to abstain from consumption of tobacco products 24.00 hours prior to dosing until the last blood sample collection of last study period.

- History of problem in swallowing Tablet(s).

- Female subject, demonstrating positive urine pregnancy test at the time of screening.

- Female subject, demonstrating positive Serum (ß) Beta- hCG (Human Chorionic Gonadotropin) test before check-in for each study period.

- Female subject, currently breast feeding or lactating.

- Female subjects not willing to use acceptable method of contraception from the date of screening until the completion of the study.

Study Design

Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
Levocetirizine Dihydrochloride tablets 5 mg
5 mg tablet once in a day
Levocetirizine Dihydrochloride
5 mg tablet once in a day

Locations

Country Name City State
India Accutest Research Lab (I) Pvt. Ltd. Ahmedabad Gujarat

Sponsors (1)

Lead Sponsor Collaborator
IPCA Laboratories Ltd.

Country where clinical trial is conducted

India, 

Outcome

Type Measure Description Time frame Safety issue
Primary Bioequivalence is based on Cmax and AUC parameters. Sampling Hours: Pre-dose and at 00.25, 00.50, 00.75, 01.00, 01.25, 01.50, 01.75, 02.00, 02.25, 02.50, 03.00, 04.00, 05.00, 06.00, 08.00, 12.00, 24.00, 36.00 and 48.00 hours post-dose. 1 month No
See also
  Status Clinical Trial Phase
Completed NCT01827878 - Bioequivalence Study of Lisinopril and Hydrochlorothiazide Tablets (20+25) mg Under Fed Conditions Phase 1
Completed NCT01721187 - Satiety Effects on the Neural Valuation of Food N/A
Completed NCT01283932 - Bioequivalence Study of Pantoprazole Sodium DR Tablets 40 mg of Dr. Reddy's Laboratories Limited Under Fed Condition Phase 1
Completed NCT01372306 - Galantamine Bioequivalence Study of Dr. Reddy's Under Fed Condition Phase 1
Completed NCT03390881 - Use of Breath Acetone aa a Marker of Energy Balance N/A
Completed NCT01283867 - Bioequivalence Study of Mycophenolate Mofetil 500 mg Tablets of Dr.Reddy's Laboratories Limited Under Non-Fasting Conditions Phase 1
Completed NCT01503450 - Bioequivalence Study of Olanzapine Orally Disintegrating Tablets, 5 mg Under Fed Condition Phase 1
Completed NCT01735383 - Bioequivalence Study of Etodolac Tablet USP 500 mg Under Fed Condition Phase 1
Completed NCT01618760 - Bioequivalence Study of Risperidone Tablet 1 mg Under Fed Condition Phase 1
Completed NCT01578265 - Bioequivalence Study of Ondansetron Tablets USP 8 mg Under Fed Condition Phase 1
Recruiting NCT05837572 - Development of the Leeds Food Preference Questionnaire in Spanish N/A
Completed NCT01618825 - Bioequivalence Study of Lamotrigine Tablets 25 mg (2 x 25 mg Tablets) Under Fed Condition Phase 1
Completed NCT01505998 - Bioequivalence Study of Amlodipine Besylate/Benazepril HCl 10 mg/40 mg Capsules of Dr. Reddy's Under Fed Conditions Phase 1
Completed NCT01735344 - Bioequivalence Study of Lisinopril Tablets 40 mg Under Fed Condition Phase 1
Completed NCT01372358 - Bioavailability Study of Ciprofloxacin 1000 mg ER Tablets of Dr. Reddy's Under Non-Fasting Conditions Phase 1
Completed NCT05995119 - Comparative Bioavailability Study of TAH3311 5 mg Oral Dissolving Film vs ELIQUIS® 5 mg Tablet in Healthy Volunteers Early Phase 1
Completed NCT01314352 - Bioavailability Study of Desloratadine 5 mg Tablet of Dr. Reddy's Under Fed Conditions Phase 1
Completed NCT01744873 - Bioequivalence Study of Bisoprolol Fumarate Tablet 10 mg Under Fed Condition Phase 1
Completed NCT01503424 - Bioequivalence Study of Olanzapine Tablets, 5 mg Under Fed Study Phase 1
Completed NCT01884909 - Bioequivalence Study of Metoprolol Succinate Extended Release Tablets 200 mg Under Fed Conditions Phase 1